Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Morphic Holding a Buy?

TheMotleyFool

0 0

On March 1, Morphic Holding's (NASDAQ: MORF) stock more than doubled after the company announced interim phase 1 data on its experimental therapy, MORF-057. That's a pretty significant pop for an under-the-radar biotech, especially based on data that comes from so early in a drug's clinical trial process.

Since then, the stock has sold off by nearly 33% from its highs. Can investors trust this biotech, which has no products on the market?

Image source: Getty Images.

Source Fool.com

Like: 0

MORF

Share